[HTML][HTML] Hepatitis C virus: Virology, diagnosis and treatment
HC Li, SY Lo - World journal of hepatology, 2015 - ncbi.nlm.nih.gov
More than twenty years of study has provided a better understanding of hepatitis C virus
(HCV) life cycle, including the general properties of viral RNA and proteins. This effort …
(HCV) life cycle, including the general properties of viral RNA and proteins. This effort …
Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis
S Iyengar, K Tay-Teo, S Vogler, P Beyer, S Wiktor… - PLoS …, 2016 - journals.plos.org
Introduction New hepatitis C virus (HCV) medicines have markedly improved treatment
efficacy and regimen tolerability. However, their high prices have limited access, prompting …
efficacy and regimen tolerability. However, their high prices have limited access, prompting …
[HTML][HTML] The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
Z Younossi, L Henry - Digestive and Liver Disease, 2014 - Elsevier
Hepatitis C is an important cause of chronic liver disease worldwide with an estimated 170
million people infected. Hepatitis C virus (HCV)-infected patients are physically and mentally …
million people infected. Hepatitis C virus (HCV)-infected patients are physically and mentally …
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C
AM Pfeil, O Reich, IM Guerra, S Cure, F Negro… - PloS one, 2015 - journals.plos.org
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C
virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of …
virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of …
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care
ZM Younossi, H Park, D Dieterich, S Saab, A Ahmed… - Medicine, 2016 - journals.lww.com
Background: New direct-acting antiviral (DAA) therapy has dramatically increased cure rates
for patients infected with hepatitis C virus (HCV), but has also substantially raised treatment …
for patients infected with hepatitis C virus (HCV), but has also substantially raised treatment …
Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV)
DR Walker, MC Pedrosa, SR Manthena, N Patel… - Advances in …, 2015 - Springer
Introduction Clinical trials have demonstrated the efficacy of all-oral direct-acting antiviral
(DAA) regimens in the treatment of patients infected with hepatitis C virus (HCV). This study …
(DAA) regimens in the treatment of patients infected with hepatitis C virus (HCV). This study …
CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections
CJ Judge, L Kostadinova, KE Sherman… - Journal of Leukocyte …, 2017 - academic.oup.com
Several lines of evidence support the concept that NK cells play an important role in control
of hepatitis C virus (HCV) infection via cytokine secretion and cytotoxicity. IL-7 is a …
of hepatitis C virus (HCV) infection via cytokine secretion and cytotoxicity. IL-7 is a …
Drug pricing evolution in hepatitis C
Objective We aimed to determine the association between the stepwise increase in the
sustained viral response (SVR) and Swiss and United States (US) market prices of drug …
sustained viral response (SVR) and Swiss and United States (US) market prices of drug …
Chronic hepatitis C: an overview of evidence on epidemiology and management from a Brazilian perspective
Chronic hepatitis C remains one of the main causes of chronic liver disease worldwide and
presents a variable natural history ranging from minimal changes to advanced fibrosis and …
presents a variable natural history ranging from minimal changes to advanced fibrosis and …
Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening
D Sarpel, E Baichoo, DT Dieterich - Expert review of anti-infective …, 2016 - Taylor & Francis
Chronic hepatitis B and C infection are the leading causes of hepatocellular carcinoma and
liver related death in the world and in the United States respectively. Screening guidelines …
liver related death in the world and in the United States respectively. Screening guidelines …